SAN DIEGO — In this video, Steven R. Bailey, MD, chief of cardiology at the University of Texas Health Sciences Center and Cardiology Today's Intervention Editorial Board member, discusses results from three late-breaking trials evaluating percutaneous valve technology presented at the American College of Cardiology Scientific Sessions.
He said that the 5-year results from PARTNER 1, 2-year data from CoreValve High Risk and 30-day from the PARTNER II S3 trials consistently indicate the benefits of transcatheter aortic valve replacement systems.
In PARTNER 1, researchers evaluated inoperable and operable patients, and found that TAVR recipients "feel better, live longer and live better" with a lower cost of care, Bailey said. He added that the 5-year data suggest continued valve performance without degeneration — and, in fact, that hemodynamics in the valve area were improved compared with surgery. The similar outcomes observed between surgery and TAVR recipients allow for confidence that TAVR is a viable alternative treatment, even among high-risk patients, Bailey said.
The CoreValve High Risk study compared the self-expanding transcatheter valve (CoreValve, Medtronic) with surgery, and the researchers observed better outcomes with the CoreValve at both 1 year and 2 years. Bailey said these results were "incredibly exciting," and stressed that these improved outcomes were present across all patient subtypes, regardless of age, sex, diabetes status or surgical risk.
The PARTNER II S3 trial evaluated 30-day outcomes from TAVR with the Sapien 3 system (Edwards Lifesciences) compared with earlier-generation devices. Bailey said there was a significant improvement in mortality and significant decrease in leak around the valve, which correlates with long-term outcomes. He added that these results suggest "significant progress" with the new TAVR technologies, which will continue to improve over time and offer further benefit for patients.
http://www.healio.com/cardiology/intervention/news/online/%7B9cb06d31-1b8a-45e9-a97d-c89f3527cc36%7D/video-results-from-three-trials-suggest-significant-progress-for-tavr-technology
He said that the 5-year results from PARTNER 1, 2-year data from CoreValve High Risk and 30-day from the PARTNER II S3 trials consistently indicate the benefits of transcatheter aortic valve replacement systems.
In PARTNER 1, researchers evaluated inoperable and operable patients, and found that TAVR recipients "feel better, live longer and live better" with a lower cost of care, Bailey said. He added that the 5-year data suggest continued valve performance without degeneration — and, in fact, that hemodynamics in the valve area were improved compared with surgery. The similar outcomes observed between surgery and TAVR recipients allow for confidence that TAVR is a viable alternative treatment, even among high-risk patients, Bailey said.
The CoreValve High Risk study compared the self-expanding transcatheter valve (CoreValve, Medtronic) with surgery, and the researchers observed better outcomes with the CoreValve at both 1 year and 2 years. Bailey said these results were "incredibly exciting," and stressed that these improved outcomes were present across all patient subtypes, regardless of age, sex, diabetes status or surgical risk.
The PARTNER II S3 trial evaluated 30-day outcomes from TAVR with the Sapien 3 system (Edwards Lifesciences) compared with earlier-generation devices. Bailey said there was a significant improvement in mortality and significant decrease in leak around the valve, which correlates with long-term outcomes. He added that these results suggest "significant progress" with the new TAVR technologies, which will continue to improve over time and offer further benefit for patients.
http://www.healio.com/cardiology/intervention/news/online/%7B9cb06d31-1b8a-45e9-a97d-c89f3527cc36%7D/video-results-from-three-trials-suggest-significant-progress-for-tavr-technology
No comments:
Post a Comment